AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 ...

Subjects in the trial received 80mg of Tagrisso daily in oral tablet form, combined with a chemotherapy regimen.

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

Positive high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) with the addition of pemetrexed and platinum-based ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO ® (osimertinib) in combination with chemotherapy demonstrated a ...

Along with the new approval, AstraZeneca announced results for the phase 3 LAURA trial, which studied osimertinib in patients with unresectable, stage III EGFRm NSCLC after chemoradiotherapy (CR ...

Several years after osimertinib was shown to deter recurrence of lung cancers, ... AstraZeneca says its drug extends life for some early-stage lung cancers. By Angus Chen March 10, 2023.

AstraZeneca’s epidermal growth factor receptor (EGFR) inhibitor, osimertinib (Tagrisso), is on the fast track in 2018 to become a first-line treatment for adult patients with locally-advanced or ...

The European Commission has approved Tagrisso (osimertinib; AstraZeneca) combined with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced ...

CHICAGO — Adjuvant osimertinib conferred a significant OS benefit vs. placebo among patients with resected, EGFR-mutant, stage IB to IIIA non-small cell lung cancer, according to results of the ...

AstraZeneca lung cancer drug halves death risk from disease, landmark study finds Results of tests on Osimertinib is hailed by experts as a ‘paradigm shift, a game changer and unequivocal’ ...

(RTTNews) - AstraZeneca Plc.'s (AZN.L, AZN) Tagrisso or osimertinib has been recommended for marketing authorization in the European Union for the adjuvant treatment of adult patients with early ...